TAC1 and neoplasm: BNCT generates alpha particles in situ via neutron capture by boron in tumor cells, differing from targeted alpha therapy (TAT) using direct alpha-emitters (e.g., 213Bi, 225Ac, and 211At) conjugated to ligands like substance P for selective tumor targeting (see Section 5.6).